Update in Treatment and Targets in Ewing Sarcoma

Hematology/Oncology Clinics of North America

Volumn 27, Issue 5, 2013, Pages 1007-1019

  Cote, Gregory M ^a   Choy, Edwin ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chemotherapy; Ewing sarcoma; Oncology; Treatment; Tumor

Indexed keywords

ANTHRACYCLINE; BUSULFAN; CIXUTUMUMAB; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FIGITUMUMAB; FLUOROURACIL; GANITUMAB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MELPHALAN; MITHRAMYCIN; OLAPARIB; R 1507; ROBATUMUMAB; TECHNETIUM 99M; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

ADD ON THERAPY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CHROMOSOME REARRANGEMENT; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG MEGADOSE; EWING SARCOMA; HIGH THROUGHPUT SEQUENCING; HUMAN; LOW DRUG DOSE; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROPHYLAXIS; RADIATION PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THORAX RADIOGRAPHY; TREATMENT DURATION;

CHEMOTHERAPY; EWING SARCOMA; ONCOLOGY; TREATMENT; TUMOR;

BONE NEOPLASMS; HUMANS; SARCOMA, EWING;

EID: 84884978493     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.07.001     Document Type: Review

References (58)

1. Askin F.B., Rosai J., Sibley R.K., et al. Malignant small cell tumor of the thoracopulmonary region in childhood: a distinctive clinicopathologic entity of uncertain histogenesis. Cancer 1979, 43:2438-2451.
2. Granowetter L., Womer R., Devidas M., et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. JClin Oncol 2009, 27:2536-2541.
3. Esiashvili N., Goodman M., Marcus R.B. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. JPediatr Hematol Oncol 2008, 30:425-430.
4. Grier H.E., Krailo M.D., Tarbell N.J., et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. NEngl J Med 2003, 348:694-701.
5. Cotterill S.J., Ahrens S., Paulussen M., et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. JClin Oncol 2000, 18:3108-3114.
6. Whelan J., McTiernan A., Cooper N., et al. Incidence and survival of malignant bone sarcomas in England 1979-2007. Int J Cancer 2012, 131:E508-E517.
7. Stiller C.A., Parkin D.M. Geographic and ethnic variations in the incidence of childhood cancer. Br Med Bull 1996, 52:682-703.
8. Randall R.L., Lessnick S.L., Jones K.B., et al. Is there a predisposition gene for Ewing's sarcoma?. JOncol 2010, 2010:397632.
9. Widhe B., Widhe T. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. JBone Joint Surg Am 2000, 82:667-674.
10. Craft A., Cotterill S., Malcolm A., et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. JClin Oncol 1998, 16:3628-3633.
11. Kissane J.M., Askin F.B., Foulkes M., et al. Ewing's sarcoma of bone: clinicopathologic aspects of 303 cases from the Intergroup Ewing's Sarcoma Study. Hum Pathol 1983, 14:773-779.
12. Gupta A.A., Pappo A., Saunders N., et al. Clinical outcome of children and adults with localized Ewing sarcoma: impact of chemotherapy dose and timing of local therapy. Cancer 2010, 116:3189-3194.
13. Nesbit M.E., Gehan E.A., Burgert E.O., et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. JClin Oncol 1990, 8:1664-1674.
14. Glaubiger D.L., Makuch R., Schwarz J., et al. Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcoma. Cancer 1980, 45:2213-2219.
15. Womer R.B., West D.C., Krailo M.D., et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. JClin Oncol 2012, 30:4148-4154.
16. Miser J.S., Krailo M.D., Tarbell N.J., et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide-a Children's Cancer Group and Pediatric Oncology Group study. JClin Oncol 2004, 22:2873-2876.
17. Paulussen M., Ahrens S., Burdach S., et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 1998, 9:275-281.
18. Paulussen M., Ahrens S., Craft A.W., et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. JClin Oncol 1998, 16:3044-3052.
19. Tan A.Y., Manley J.L. The TET family of proteins: functions and roles in disease. JMol Cell Biol 2009, 1:82-92.
20. Jain S., Xu R., Prieto V.G., et al. Molecular classification of soft tissue sarcomas and its clinical applications. Int J Clin Exp Pathol 2010, 3:416-428.
21. Peter M., Couturier J., Pacquement H., et al. Anew member of the ETS family fused to EWS in Ewing tumors. Oncogene 1997, 14:1159-1164.
22. Turc-Carel C., Aurias A., Mugneret F., et al. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 1988, 32:229-238.
23. Downing J.R., Head D.R., Parham D.M., et al. Detection of the (11;22)(q24;q12) translocation of Ewing's sarcoma and peripheral neuroectodermal tumor by reverse transcription polymerase chain reaction. Am J Pathol 1993, 143:1294-1300.
24. Zucman J., Melot T., Desmaze C., et al. Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J 1993, 12:4481-4487.
25. Sorensen P.H., Lessnick S.L., Lopez-Terrada D., et al. Asecond Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994, 6:146-151.
26. Bielack S.S., Paulussen M., Kohler G. Apatient with two Ewing's sarcomas with distinct EWS fusion transcripts. NEngl J Med 2004, 350:1364-1365.
27. Jeon I.S., Davis J.N., Braun B.S., et al. Avariant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene 1995, 10:1229-1234.
28. Smith M.A., Ungerleider R.S., Horowitz M.E., et al. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. JNatl Cancer Inst 1991, 83:1460-1470.
29. Burgert E.O., Nesbit M.E., Garnsey L.A., et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. JClin Oncol 1990, 8:1514-1524.
30. Antman K.H., Ryan L., Elias A., et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. JClin Oncol 1989, 7:126-131.
31. Jurgens H., Exner U., Kuhl J., et al. High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma. Cancer Chemother Pharmacol 1989, 24(Suppl 1):S40-S44.
32. Magrath I., Sandlund J., Raynor A., et al. Aphase II study of ifosfamide in the treatment of recurrent sarcomas in young people. Cancer Chemother Pharmacol 1986, 18(Suppl 2):S25-S28.
33. Miser J.S., Kinsella T.J., Triche T.J., et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. JClin Oncol 1987, 5:1191-1198.
34. Kung F.H., Pratt C.B., Vega R.A., et al. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. Cancer 1993, 71:1898-1903.
35. Bacci G., Picci P., Ferrari S., et al. Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase-results of two sequential studies. Cancer 1998, 82:1174-1183.
36. Bacci G., Mercuri M., Longhi A., et al. Neoadjuvant chemotherapy for Ewing's tumour of bone: recent experience at the Rizzoli Orthopaedic Institute. Eur J Cancer 2002, 38:2243-2251.
37. Wexler L.H., DeLaney T.F., Tsokos M., et al. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer 1996, 78:901-911.
38. Ladenstein R., Potschger U., Le Deley M.C., et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. JClin Oncol 2010, 28:3284-3291.
39. Choy E., Digumarthy S.R., Koplin S.A. Case records of the Massachusetts General Hospital. Case 36-2009. A 23-year-old man with cough, hoarseness, and abnormalities on chest imaging. NEngl J Med 2009, 361:2080-2087.
40. Juergens C., Weston C., Lewis I., et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 2006, 47:22-29.
41. Van Winkle P., Angiolillo A., Krailo M., et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr Blood Cancer 2005, 44:338-347.
42. Navid F., Willert J.R., McCarville M.B., et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 2008, 113:419-425.
43. Bernstein M.L., Devidas M., Lafreniere D., et al. Intensive therapy with growthfactor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457-areport from the Children's Oncology Group. JClin Oncol 2006, 24:152-159.
44. Hunold A., Weddeling N., Paulussen M., et al. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 2006, 47:795-800.
45. Wagner L.M., McAllister N., Goldsby R.E., et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007, 48:132-139.
46. Casey D.A., Wexler L.H., Merchant M.S., et al. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2009, 53:1029-1034.
47. Stegmaier K., Wong J.S., Ross K.N., et al. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med 2007, 4:e122.
48. DuBois S.G., Krailo M.D., Lessnick S.L., et al. Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009, 52:324-327.
49. Grohar P.J., Woldemichael G.M., Griffin L.B., et al. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. JNatl Cancer Inst 2011, 103:962-978.
50. Boro A., Pretre K., Rechfeld F., et al. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma. Int J Cancer 2012, 131:2153-2164.
51. Erkizan H.V., Kong Y., Merchant M., et al. Asmall molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 2009, 15:750-756.
52. Garnett M.J., Edelman E.J., Heidorn S.J., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575.
53. Brenner J.C., Feng F.Y., Han S., et al. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res 2012, 72:1608-1613.
54. Kurzrock R., Patnaik A., Aisner J., et al. Aphase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 2010, 16:2458-2465.
55. Haluska P., Worden F., Olmos D., et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 2010, 65:765-773.
56. Olmos D., Postel-Vinay S., Molife L.R., et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010, 11:129-135.
57. Juergens H., Daw N.C., Geoerger B., et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. JClin Oncol 2011, 29:4534-4540.
58. Pappo A.S., Patel S.R., Crowley J., et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. JClin Oncol 2011, 29:4541-4547.